|
|
|
|
Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGl1 antibody-associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy. |
|